

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 October 2003 (16.10.2003)

PCT

(10) International Publication Number
WO 03/084540 A2

(51) International Patent Classification⁷: **A61K 31/445**,
39/395, 31/7088, A61P 25/02, C12Q 1/37

(21) International Application Number: PCT/EP03/03643

(22) International Filing Date: 8 April 2003 (08.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/371,042 9 April 2002 (09.04.2002) US

(71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, 1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BUXTON, Francis, Paul** [GB/US]; 6 Applewood Lane, Morristown, NJ 07960 (US). **FOX, Alyson** [GB/GB]; The Novartis Institute for Medical Sciences, 5 Gower Place, London, WC1E 6BN (GB). **GANJU, Pamposh** [GB/GB]; Novartis Institute for Medical Sciences, University College, 5 Gower Place, London WC1E 6BN (GB). **GRAY, Andrew, J.** [GB/GB];

Novartis Institute for Medical Sciences, 5 Gower Place, London, WC1E 6BN (GB). **SONG, CHUANZHENG** [CN/US]; 87 Reinman Road, Warren, NJ 07059 (US). **URBAN, Laszlo** [GB/GB]; The Novartis Institute for Medical Sciences, 5 Gower Place, London, WC1E 6BN (GB).

(74) Agents: **GROS, Florent et al.**; NOVARTIS AG., Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR THE TREATMENT OF CHRONIC PAIN AND COMPOSITIONS THEREFOR

(57) Abstract: The invention discloses MMP7 as a suitable target for the development of new therapeutics to treat or ameliorate chronic pain. The invention relates to methods to treat and/or ameliorate chronic pain and pharmaceutical compositions therefor comprising modulators with inhibitory effect on MMP7 enzyme activity and/or MMP7 gene expression. The invention also relates to a method to identify compounds with therapeutic usefulness to treat chronic pain, comprising identifying compounds that can inhibit MMP7 activity and/or gene expression which can also reverse the pathological effects of chronic pain in vivo.

WO 03/084540 A2